Endpoints
thrombocytopenia, death
THROMBOEMBOLIC EVENT, RECURRENCE, RECURRENCE, THROMBOCYTOPENIA, ITTP
The primary endpoint of the study was the proportion of participants with a recurrence of iTTP during the overall study period and was assessed in the per-protocol (PP) population. Recurrence was defined as recurrent thrombocytopenia after initial recovery of platelet count (confirmed platelet count ≥ 150 × 10Secondary endpoints, assessed in the PP and modified intention-to-treat (mITT) populations, included the composite endpoint of iTTP-related death, iTTP recurrence, or ≥ 1 treatment-emergent major thromboembolic event; the proportion of participants with refractory iTTP (persistent thrombocytopenia, lack of a sustained platelet count increment or platelet count < 50 × 10